Cogent Biosciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

COGT$31.64-5.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Series A Non-Voting Convertible PreferredStock · Series B Non-Voting Convertible PreferredStock · Common Stock · AdditionalPaid-in · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balances at December 31, 2025	67,414	$53,830	4,516	$35,563	160,980,024	$161	$1,734,882	$355	$(1,188,420)	$636,371
Issuance of common stock under Employee Stock Purchase Plan	—	—	—	—	173,128	—	1,062	—	—	1,062
Issuance of common stock upon RSU vesting	—	—	—	—	3,200	—	—	—	—	—
Issuance of common stock under ATM, net of issuance costs of $1.4 million	—	—	—	—	1,340,699	1	45,711	—	—	45,712
Issuance of common stock from exercises of stock options	—	—	—	—	670,692	1	5,755	—	—	5,756
Issuance of common stock from pre-funded warrant exercises	—	—	—	—	606,060	1	5	—	—	6
Conversion of Series A non-voting preferred stock into common stock	(28,000)	(24,640)	—	—	7,000,000	7	24,633	—	—	—
Unrealized losses on marketable securities	—	—	—	—	—	—	—	(770)	—	(770)
Stock-based compensation expense	—	—	—	—	—	—	16,908	—	—	16,908
Net loss	—	—	—	—	—	—	—	—	(97,352)	(97,352)
Balances at March 31, 2026	39,414	$29,190	4,516	$35,563	170,773,803	$171	$1,828,956	$(415)	$(1,285,772)	$607,693
Issuance of common stock from exercises of stock options	—	—	—	—	484,606	—	4,348	—	—	4,348
Issuance of common stock upon PSU vesting	—	—	—	—	340,000	—	—	—	—	—
Unrealized losses on marketable securities	—	—	—	—	—	—	—	(355)	—	(355)
Stock-based compensation expense	—	—	—	—	—	—	17,107	—	—	17,107
Net loss	—	—	—	—	—	—	—	—	(96,405)	(96,405)
Balances at June 30, 2026	39,414	$29,190	4,516	$35,563	171,598,409	$171	$1,850,411	$(770)	$(1,382,177)	$532,388

Series A Non-Voting Convertible PreferredStock · Series B Non-Voting Convertible PreferredStock · Common Stock · AdditionalPaid-in · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’
Shares · Amount · Shares · Amount · Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balances at December 31, 2024	70,465	$56,515	6,868	$54,085	110,461,729		$110		$1,004,612		$447		$(859,483)	$256,286
Issuance of common stock under ATM, net of issuance costs of $0.7 million	—	—	—	—	2,587,992		3		24,247		—		—	24,250
Conversion of Series A non-voting preferred stock into common stock	(2,767)	(2,435)	—	—	691,750		1		2,434		—		—	—
Issuance of common stock from exercises of stock options	—	—	—	—	26,842		—		136		—		—	136
Issuance of common stock under Employee Stock Purchase Plan	—	—	—	—	88,141		—		584		—		—	584
Unrealized losses on marketable securities	—	—	—	—	—		—		—		(283)		—	(283)
Stock-based compensation expense						10,008		—		—		10,008
Net loss	—	—	—	—	—		—		—		—		(71,986)	(71,986)
Balances at March 31, 2025	67,698	$54,080	6,868	$54,085	113,856,454		$114		$1,042,021		$164		$(931,469)	$218,995
Conversion of Series A non-voting preferred stock into common stock	(284)	(250)	—	—	71,000		—		250		—		—	—
Issuance of common stock from exercises of stock options	—	—	—	—	1,038		—		5		—		—	5
Unrealized losses on marketable securities	—	—	—	—	—		—		—		(151)		—	(151)
Stock-based compensation expense						9,716		—		—		9,716
Net loss	—	—	—	—	—		—		—		—		(73,529)	(73,529)
Balances at June 30, 2025	67,414	$53,830	6,868	$54,085	113,928,492		$114		$1,051,992		$13		$(1,004,998)	$155,036

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.